{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:12:03Z","timestamp":1788999123477,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Male germ cell tumors (GCT) have excellent survival. Long-term sequelae in cancer survivors are an evolving field. We evaluated the risk of patients with GCT to develop primary hypogonadism and adherence to guideline-recommended therapy in a real-world cohort. Monocentric study at a tertiary cancer centre to evaluate treated GCT-patients (2001\u20132019). Post therapeutic male endocrine function, International Index of Erectile Function (IIEF)-5 and The aging males\u2019 symptoms rating scale (AMS) questionnaires were assessed. The overall response rates were low, with 44 of 402 contacted patients participating in the study. From these, 32(73%) underwent blood analysis, 42(95%) answered the IIEF-5 and 43(98%) the AMS. Latent hypogonadism (serum testosterone 8\u201312 nmol\/l) was found in <jats:italic>n<\/jats:italic>\u2009=\u20099 (28%) and manifest hypogonadism (testosterone\u2009&lt;\u20098 nmol\/l) in <jats:italic>n<\/jats:italic>\u2009=\u20098 (25%). 50% (<jats:italic>n<\/jats:italic>\u2009=\u200921) indicated erectile dysfunction on IIEF-5 (cut off \u2264\u200921 pts.) and 62.8% (<jats:italic>n<\/jats:italic>\u2009=\u200927) reported symptomatic affection on AMS (cut off \u2265\u200927 pts.). Majority of tested patients revealed different degrees of hypogonadism. Standard instruments were able to detect gonadal damage in &gt;\u200950%, which underscored the clinical need to evaluate endocrine function in cancer survivors. We further indicated the difficulties of today\u2019s research and provided starting points to assess barriers for study participations.<\/jats:p>","DOI":"10.1038\/s41598-024-78765-w","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T08:46:48Z","timestamp":1731660408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The effect of chemotherapy regimens in male germ cell tumors on the development of primary hypogonadism"],"prefix":"10.1038","volume":"14","author":[{"given":"Analena","family":"Handke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marla Geller-von","family":"Bargen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykhan","family":"Isgandarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulham","family":"al Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"P\u00fcllen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"78765_CR1","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1200\/JCO.20.00722","volume":"38","author":"C Chao","year":"2020","unstructured":"Chao, C. et al. Chronic comorbidities among survivors of adolescent and young adult Cancer. J. Clin. Oncol. 38, 3161\u20133174. https:\/\/doi.org\/10.1200\/JCO.20.00722 (2020).","journal-title":"J. Clin. Oncol."},{"key":"78765_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/S00761-016-0174-6","volume":"23","author":"J Bertz","year":"2017","unstructured":"Bertz, J., Buttmann-Schweiger, N. & Kraywinkel, K. Epidemiologie b\u00f6sartiger Hodentumoren in Deutschland. Onkologe 23, 90\u201396. https:\/\/doi.org\/10.1007\/S00761-016-0174-6 (2017).","journal-title":"Onkologe"},{"key":"78765_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1200\/JCO.20.03296","volume":"39","author":"S Gillessen","year":"2021","unstructured":"Gillessen, S. et al. Predicting outcomes in Men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium. J. Clin. Oncol. 39, 1563\u20131574. https:\/\/doi.org\/10.1200\/JCO.20.03296 (2021).","journal-title":"J. Clin. Oncol."},{"key":"78765_CR4","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.20.03292","volume":"39","author":"J Beyer","year":"2021","unstructured":"Beyer, J. et al. Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium. J. Clin. Oncol. 39, 1553\u20131562. https:\/\/doi.org\/10.1200\/JCO.20.03292 (2021).","journal-title":"J. Clin. Oncol."},{"key":"78765_CR5","unstructured":"EAU Guidelines. In Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6  (2023)."},{"key":"78765_CR6","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK A. S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens. Langversion 1.1. (2020,. accessed 30 Mar 2024). www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Hodentumoren\/LL_Hodentumoren_Langversion_1.1.pdf."},{"key":"78765_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0302-2838(03)00263-X","volume":"44","author":"C Nord","year":"2003","unstructured":"Nord, C. et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur. Urol. 44, 322\u2013328. https:\/\/doi.org\/10.1016\/S0302-2838(03)00263-X (2003).","journal-title":"Eur. Urol."},{"key":"78765_CR8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/J.EURURO.2007.05.012","volume":"52","author":"P Wiechno","year":"2007","unstructured":"Wiechno, P., Demkow, T., Kubiak, K., Sadowska, M. & Kami\u0144ska, J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur. Urol. 52, 1448\u20131455. https:\/\/doi.org\/10.1016\/J.EURURO.2007.05.012 (2007).","journal-title":"Eur. Urol."},{"key":"78765_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/NCPENDMET1050","volume":"5","author":"BB Yeap","year":"2009","unstructured":"Yeap, B. B. Testosterone and ill-health in aging men. Nat. Clin. Pract. Endocrinol. Metab. 5, 113\u2013121. https:\/\/doi.org\/10.1038\/NCPENDMET1050 (2009).","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"78765_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/SJ.BJC.6602677","volume":"93","author":"RA Huddart","year":"2005","unstructured":"Huddart, R. A. et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br. J. Cancer. 93, 200\u2013207. https:\/\/doi.org\/10.1038\/SJ.BJC.6602677 (2005).","journal-title":"Br. J. Cancer"},{"key":"78765_CR11","doi-asserted-by":"publisher","unstructured":"P\u00fchse, G. et al. Phantom testis syndrome: prevalence, phenomenology and putative mechanisms. Int. J. Androl. 33 https:\/\/doi.org\/10.1111\/J.1365-2605.2009.00994.X (2010).","DOI":"10.1111\/J.1365-2605.2009.00994.X"},{"key":"78765_CR12","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1007\/S00520-019-05117-0","volume":"28","author":"N Khanal","year":"2020","unstructured":"Khanal, N. et al. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy. Support Care Cancer  28, 3165\u20133170. https:\/\/doi.org\/10.1007\/S00520-019-05117-0 (2020).","journal-title":"Support Care Cancer"},{"key":"78765_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/sj.ijir.3900857","volume":"14","author":"RC Rosen","year":"2002","unstructured":"Rosen, R. C., Cappelleri, J. C. & Gendrano, N. The International Index of Erectile function (IIEF): a state-of-the-science review. Int. J. Impot. Res. 2002. 14, 4. https:\/\/doi.org\/10.1038\/sj.ijir.3900857 (2002).","journal-title":"Int. J. Impot. Res. 2002"},{"key":"78765_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/J.JSXM.2019.04.010","volume":"16","author":"KI Neijenhuijs","year":"2019","unstructured":"Neijenhuijs, K. I. et al. The International Index of Erectile function (IIEF)-A systematic review of Measurement Properties. J. Sex. Med. 16, 1078\u20131091. https:\/\/doi.org\/10.1016\/J.JSXM.2019.04.010 (2019).","journal-title":"J. Sex. Med."},{"key":"78765_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","volume":"49","author":"RC Rosen","year":"1997","unstructured":"Rosen, R. C. et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology  49, 822\u2013830. https:\/\/doi.org\/10.1016\/S0090-4295(97)00238-0 (1997).","journal-title":"Urology"},{"key":"78765_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/13685539909003173","volume":"2","author":"LAJ Heinemann","year":"2009","unstructured":"Heinemann, L. A. J., Zimmermann, T., Vermeulen, A., Thiel, C. & Hummel, W. A new \u2018aging males\u2019 symptoms\u2019 rating scale. World J. Mens Health 2, 105\u2013114. https:\/\/doi.org\/10.3109\/13685539909003173 (2009).","journal-title":"Https:\/\/DoiOrg\/103109\/13685539909003173"},{"key":"78765_CR17","doi-asserted-by":"publisher","unstructured":"Tsuru, T. et al. International prostate symptom score and quality of Life Index for lower urinary tract symptoms are Associated with Aging males symptoms rating scale for late-onset hypogonadism symptoms. World J. Mens Health 2023, 41. https:\/\/doi.org\/10.5534\/WJMH.210171 (2023).","DOI":"10.5534\/WJMH.210171"},{"key":"78765_CR18","doi-asserted-by":"publisher","unstructured":"Thepwiwatjit, S. et al. Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis. J. Scleroderma Relat. Disord 2022, 7. https:\/\/doi.org\/10.1177\/23971983221112021 (2022).","DOI":"10.1177\/23971983221112021"},{"key":"78765_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/ANDR.12147","volume":"4","author":"G Chiriac\u00f2","year":"2016","unstructured":"Chiriac\u00f2, G., Cauci, S., Mazzon, G. & Trombetta, C. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology 4, 245\u2013250. https:\/\/doi.org\/10.1111\/ANDR.12147 (2016).","journal-title":"Andrology"},{"key":"78765_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1177\/1557988317703207","volume":"11","author":"KS Fugl-Meyer","year":"2017","unstructured":"Fugl-Meyer, K. S., Nilsson, M., Hylander, B. & Lehtihet, M. Sexual function and testosterone level in men with conservatively treated chronic kidney disease. Am. J. Mens. Health 11, 1069\u20131076. https:\/\/doi.org\/10.1177\/1557988317703207 (2017).","journal-title":"Am. J. Mens. Health"},{"key":"78765_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4158\/EP.8.6.439","volume":"8","author":"SM Petak","year":"2002","unstructured":"Petak, S. M., Nankin, H. R., Spark, R. F., Swerdloff, R. S. & Rodriguez-Rigau, L. J. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients\u20132002 update. Endocr. Pract. 8, 439\u2013456. https:\/\/doi.org\/10.4158\/EP.8.6.439 (2002).","journal-title":"Endocr. Pract."},{"key":"78765_CR22","doi-asserted-by":"publisher","unstructured":"Khanal, N. et al. Hypogonadism and effects on quality of life in previously treated germ cell tumor survivors: a single-centre, non-randomized, prospective observational study. Urol. Oncol. 36, 10079\u201310079. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_SUPPL.10079 (2018).","DOI":"10.1200\/JCO.2018.36.15_SUPPL.10079"},{"key":"78765_CR23","doi-asserted-by":"publisher","unstructured":"Hartung, T. J. et al. Age-related variation and predictors of long-term quality of life in germ cell tumor survivors. Urol. Oncol. 34, 60.e1-60.e6. https:\/\/doi.org\/10.1016\/J.UROLONC.2015.09.005 (2016).","DOI":"10.1016\/J.UROLONC.2015.09.005"},{"key":"78765_CR24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1200\/JCO.2011.40.8922","volume":"31","author":"H Faller","year":"2013","unstructured":"Faller, H. et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J. Clin. Oncol. 31, 782\u2013793. https:\/\/doi.org\/10.1200\/JCO.2011.40.8922 (2013).","journal-title":"J. Clin. Oncol."},{"key":"78765_CR25","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1200\/JCO.2008.19.6931","volume":"27","author":"PB Rossen","year":"2009","unstructured":"Rossen, P. B., Pedersen, A. F., Zachariae, R. & Von Der Maase, H. Health-related quality of life in long-term survivors of testicular cancer. J. Clin. Oncol. 27, 5993\u20135999. https:\/\/doi.org\/10.1200\/JCO.2008.19.6931 (2009).","journal-title":"J. Clin. Oncol."},{"key":"78765_CR26","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/S00520-015-3026-9","volume":"24","author":"K Oechsle","year":"2016","unstructured":"Oechsle, K. et al. Symptom burden in long-term germ cell tumor survivors. Support Care Cancer. 24, 2243\u20132250. https:\/\/doi.org\/10.1007\/S00520-015-3026-9 (2016).","journal-title":"Support Care Cancer"},{"key":"78765_CR27","unstructured":"S3-Leitlinie Keimzelltumoren des Hodens. | Enhanced Reader (2023)."},{"key":"78765_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13063-022-06748-1\/TABLES\/4","volume":"23","author":"D Abdulhussein","year":"2022","unstructured":"Abdulhussein, D., Yap, T. E., Manzar, H., Miodragovic, S. & Cordeiro, F. Factors impacting participation in research during the COVID-19 pandemic: results from a survey of patients in the ophthalmology outpatient department. Trials 23, 1\u20139. https:\/\/doi.org\/10.1186\/S13063-022-06748-1\/TABLES\/4 (2022).","journal-title":"Trials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78765-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T09:07:07Z","timestamp":1731661627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-78765-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["78765"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-78765-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CD has advisory roles for Janssen and IPSEN and has received travel compensation from Janssen, IPSEN and BayerB.H. has had advisory roles for ABX, AAA\/Novartis, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen R&D, Lightpoint Medical, Inc., and Pfizer; has received research funding from Astellas, Bristol Myers Squibb, AAA\/Novartis, German Research Foundation, Janssen R&D, and Pfizer; and has received compensation for travel from Astellas, AstraZeneca, Bayer and Janssen R&D. A.H, MGvB, AI, MN, UK, LP declare no conflicts of interest.VG: receiving grant support, lecture fees, consulting fees, and travel support from AstraZeneca, BMS, Ipsen, and Pfizer, consulting fees and travel support from Bayer, grant support, lecture fees, and consulting fees from MSD, consulting fees from Roche, Eli Lilly, Onkowissen, and EUSA Pharma, consulting fees and lecture fees from Janssen\u2013 Cilag, PharmaMar, Merck Serono, and Eisai, lecture fees from Asklepios Clinic, Diakonie Clinic, Dortmund Hospital, andClinic of Oldenburg, and grant support and consulting fees from Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study protocol was reviewed and approved by the local ethics committee of University Duisburg-Essen (21-9860-BO) and conducted in accordance with the ethical standards of the Declaration of Helsinki. The participants provided informed written consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"28141"}}